{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:02:45Z","timestamp":1790355765520,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Obesity is a\u00a0rapidly increasing global health challenge that is strongly linked to the cardiorenometabolic syndrome, cardiovascular morbidity, and mortality. Lifestyle interventions remain the cornerstone of treatment, but average long-term weight loss is modest and durable weight maintenance is often limited. Bariatric surgery is not suitable for all patients, and substantial weight regain occurs in a\u00a0considerable proportion over time. Glucagon-like peptide\u20111 receptor agonists (GLP-1RAs), originally developed for type\u00a02 diabetes (T2D), have emerged as potent agents for weight reduction and cardiometabolic risk improvement. By enhancing glucose-dependent insulin secretion, suppressing appetite, improving lipid metabolism, and exerting anti-inflammatory, endothelial, and haemodynamic effects, GLP-1RAs influence multiple pathways relevant to cardiovascular disease.<\/jats:p>\n                  <jats:p>Across large cardiovascular-outcome trials, GLP-1RAs consistently reduce major adverse cardiovascular events (MACE), all-cause mortality, and heart-failure hospitalizations in individuals with T2D. In populations with overweight or obesity without diabetes, semaglutide, as shown in the SELECT trial, has demonstrated significant cardiovascular risk reduction, partly independent of weight loss. Overall, GLP-1RAs represent a\u00a0therapeutic option for cardiovascular prevention across a\u00a0broad spectrum of patients at high-risk for or with established CVD. This review provides a\u00a0comprehensive overview of the pleiotropic cardiovascular effects associated with GLP-1RAs and discusses their potential integration into cardiovascular care.<\/jats:p>","DOI":"10.1007\/s12471-026-02073-3","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:01:11Z","timestamp":1789344071000},"page":"352-362","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of GLP-1 receptor agonists on body weight and cardiovascular outcomes: a\u00a0review"],"prefix":"10.1007","volume":"34","author":[{"given":"Susan J. F.","family":"van Maren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eveline P. M.","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cees J. J.","family":"Tack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth F. C.","family":"van Rossum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saloua","family":"El Messaoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"2073_CR1","unstructured":"World Health Organization. Obesity and overweight. 2025. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"issue":"17","key":"2073_CR2","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1093\/eurjpc\/zwac187","volume":"29","author":"F Lopez-Jimenez","year":"2022","unstructured":"Lopez-Jimenez\u00a0F, Almahmeed\u00a0W, Bays\u00a0H, et\u00a0al. Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation. Eur J Prev Cardiol. 2022;29(17):2218\u201337.","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"2073_CR3","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1210\/en.2013-1934","volume":"155","author":"C Pyke","year":"2014","unstructured":"Pyke\u00a0C, Heller\u00a0RS, Kirk\u00a0RK, et\u00a0al. GLP\u20111 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody. Endocrinology. 2014;155(4):1280\u201390.","journal-title":"Endocrinology"},{"issue":"6","key":"2073_CR4","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s12325-021-01710-0","volume":"38","author":"J Ard","year":"2021","unstructured":"Ard\u00a0J, Fitch\u00a0A, Fruh\u00a0S, Herman\u00a0L. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. Adv Ther. 2021;38(6):2821\u201339.","journal-title":"Adv Ther"},{"issue":"6","key":"2073_CR5","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1530\/eje.0.1460863","volume":"146","author":"H Hui","year":"2002","unstructured":"Hui\u00a0H, Farilla\u00a0L, Merkel\u00a0P, Perfetti\u00a0R. The short half-life of glucagon-like peptide\u20111 in plasma does not reflect its long-lasting beneficial effects. Eur J Endocrinol. 2002;146(6):863\u20139.","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2073_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3699","volume":"39","author":"MM Smits","year":"2023","unstructured":"Smits\u00a0MM, Holst\u00a0JJ. Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP\u20111 receptor agonists: Could this work and how? Diabetes Metab Res Rev. 2023;39(8)e3699.","journal-title":"Diabetes Metab Res Rev"},{"key":"2073_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.addr.2018.07.009","volume":"130","author":"M Yu","year":"2018","unstructured":"Yu\u00a0M, Benjamin\u00a0MM, Srinivasan\u00a0S, et\u00a0al. Battle of GLP\u20111 delivery technologies. Adv Drug Deliv Rev. 2018;130:113\u201330.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"2073_CR8","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1210\/jcem.87.3.8355","volume":"87","author":"MA Nauck","year":"2002","unstructured":"Nauck\u00a0MA, Heimesaat\u00a0MM, Behle\u00a0K, et\u00a0al. Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers. J\u00a0Clin Endocrinol Metab. 2002;87(3):1239\u201346.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2073_CR9","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/dom.13120","volume":"20","author":"JB Hjerpsted","year":"2018","unstructured":"Hjerpsted\u00a0JB, Flint\u00a0A, Brooks\u00a0A, et\u00a0al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018;20(3):610\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"2073_CR10","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1210\/en.2018-00004","volume":"159","author":"LL Baggio","year":"2018","unstructured":"Baggio\u00a0LL, Yusta\u00a0B, Mulvihill\u00a0EE, et\u00a0al. GLP\u20111 Receptor Expression Within the Human Heart. Endocrinology. 2018;159(4):1570\u201384.","journal-title":"Endocrinology"},{"issue":"2","key":"2073_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1479164111404257","volume":"8","author":"T Gaspari","year":"2011","unstructured":"Gaspari\u00a0T, Liu\u00a0HB, Welungoda\u00a0I, et\u00a0al. A GLP\u20111 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-\/- mouse model. Diabetes Vasc Dis Res. 2011;8(2):117\u201324.","journal-title":"Diabetes Vasc Dis Res"},{"issue":"7","key":"2073_CR12","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1161\/ATVBAHA.110.206425","volume":"30","author":"H Oeseburg","year":"2010","unstructured":"Oeseburg\u00a0H, de Boer\u00a0RA, Buikema\u00a0H, et\u00a0al. Glucagon-Like Peptide 1 Prevents Reactive Oxygen Species-Induced Endothelial Cell Senescence Through the Activation of Protein Kinase A. Arterioscler Thromb Vasc Biol. 2010;30(7):1407\u201314.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"2073_CR13","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.2337\/db14-0976","volume":"64","author":"J Koska","year":"2015","unstructured":"Koska\u00a0J, Sands\u00a0M, Burciu\u00a0C, et\u00a0al. Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP\u20111 Receptor Agonists in Humans. Diabetes. 2015;64(7):2624\u201335.","journal-title":"Diabetes"},{"issue":"3","key":"2073_CR14","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3390\/jcm12030772","volume":"12","author":"C Kennedy","year":"2023","unstructured":"Kennedy\u00a0C, Hayes\u00a0P, Salama\u00a0S, et\u00a0al. The Effect of Semaglutide on Blood Pressure in Patients without Diabetes: A Systematic Review and Meta-Analysis. J\u00a0Clin Med. 2023;12(3):772\u2013772.","journal-title":"J Clin Med"},{"issue":"1","key":"2073_CR15","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.clinthera.2014.11.008","volume":"37","author":"F Sun","year":"2015","unstructured":"Sun\u00a0F, Wu\u00a0S, Wang\u00a0J, et\u00a0al. Effect of Glucagon-like Peptide\u20111 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Clin Ther. 2015;37(1):225\u2013241.e8.","journal-title":"Clin Ther"},{"issue":"9","key":"2073_CR16","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s00125-017-4330-3","volume":"60","author":"\u00c1 Vinu\u00e9","year":"2017","unstructured":"Vinu\u00e9 \u00c1, Navarro\u00a0J, Herrero-Cervera\u00a0A, et\u00a0al. The GLP\u20111 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype. Diabetologia. 2017;60(9):1801\u201312.","journal-title":"Diabetologia"},{"issue":"4","key":"2073_CR17","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.2337\/db09-1694","volume":"59","author":"M Arakawa","year":"2010","unstructured":"Arakawa\u00a0M, Mita\u00a0T, Azuma\u00a0K, et\u00a0al. Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide\u20111 Receptor Agonist, Exendin\u20114. Diabetes. 2010;59(4):1030\u20137.","journal-title":"Diabetes"},{"issue":"6","key":"2073_CR18","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","volume":"3","author":"G Rakipovski","year":"2018","unstructured":"Rakipovski\u00a0G, Rolin\u00a0B, N\u00f8hr\u00a0J, et\u00a0al. The GLP\u20111 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE\u2212\/\u2212 and LDLr\u2212\/\u2212 Mice by a Mechanism That Includes Inflammatory Pathways. JACC Basic Transl Sci. 2018;3(6):844\u201357.","journal-title":"JACC Basic Transl Sci"},{"issue":"1","key":"2073_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1536\/ihj.19-327","volume":"61","author":"J Chen","year":"2020","unstructured":"Chen\u00a0J, Xu\u00a0S, Zhou\u00a0W, Wu\u00a0L, Wang\u00a0L, Li\u00a0W. Exendin\u20114 Reduces Ventricular Arrhythmia Activity and Calcium Sparks-Mediated Sarcoplasmic Reticulum Ca Leak in Rats with Heart Failure. Int Heart J. 2020;61(1):145\u201352.","journal-title":"Int Heart J"},{"issue":"18","key":"2073_CR20","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","volume":"117","author":"K Ban","year":"2008","unstructured":"Ban\u00a0K, Noyan-Ashraf\u00a0MH, Hoefer\u00a0J, et\u00a0al. Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor-Dependent and -Independent Pathways. Circulation. 2008;117(18):2340\u201350.","journal-title":"Circulation"},{"issue":"9","key":"2073_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd10090386","volume":"10","author":"Y Zhou","year":"2023","unstructured":"Zhou\u00a0Y, Yuan\u00a0Z, Wang\u00a0M, et\u00a0al. Liraglutide Attenuates Aortic Valve Calcification in a High-Cholesterol-Diet-Induced Experimental Calcific Aortic Valve Disease Model in Apolipoprotein E\u2011Deficient Mice. J\u00a0Cardiovasc Dev Dis. 2023;10(9)386.","journal-title":"J Cardiovasc Dev Dis"},{"issue":"21","key":"2073_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13216411","volume":"13","author":"P Karakasis","year":"2024","unstructured":"Karakasis\u00a0P, Patoulias\u00a0D, Giannakoulas\u00a0G, et\u00a0al. Effect of Glucagon-like Peptide\u20111 Receptor Agonism on Aortic Valve Stenosis Risk: A Mendelian Randomization Analysis. J\u00a0Clin Med. 2024;13(21)6411.","journal-title":"J Clin Med"},{"key":"2073_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1431292","volume":"15","author":"QK Liu","year":"2024","unstructured":"Liu\u00a0QK. Mechanisms of action and therapeutic applications of GLP\u20111 and dual GIP\/GLP\u20111 receptor agonists. Front Endocrinol (Lausanne). 2024;15:1431292.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"23","key":"2073_CR24","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer\u00a0MA, Claggett\u00a0B, Diaz\u00a0R, et\u00a0al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373(23):2247\u201357.","journal-title":"N Engl J Med"},{"issue":"13","key":"2073_CR25","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman\u00a0RR, Bethel\u00a0MA, Mentz\u00a0RJ, et\u00a0al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(13):1228\u201339.","journal-title":"N Engl J Med"},{"issue":"4","key":"2073_CR26","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso\u00a0SP, Daniels\u00a0GH, Brown-Frandsen\u00a0K, et\u00a0al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"19","key":"2073_CR27","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso\u00a0SP, Bain\u00a0SC, Consoli\u00a0A, et\u00a0al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"10157","key":"2073_CR28","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez\u00a0AF, Green\u00a0JB, Janmohamed\u00a0S, et\u00a0al. Albiglutide and cardiovascular outcomes in patients with type\u00a02 diabetes and cardiovascular disease (Harmony Outcomes): a\u00a0double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519\u201329.","journal-title":"Lancet"},{"issue":"10193","key":"2073_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein\u00a0HC, Colhoun\u00a0HM, Dagenais\u00a0GR, et\u00a0al. Dulaglutide and cardiovascular outcomes in type\u00a02 diabetes (REWIND): a\u00a0double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"issue":"10","key":"2073_CR30","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein\u00a0HC, Sattar\u00a0N, Rosenstock\u00a0J, et\u00a0al. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. N Engl J Med. 2021;385(10):896\u2013907.","journal-title":"N Engl J Med"},{"issue":"20","key":"2073_CR31","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire\u00a0DK, Marx\u00a0N, Mulvagh\u00a0SL, et\u00a0al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025;392(20):2001\u201312.","journal-title":"N Engl J Med"},{"issue":"5","key":"2073_CR32","first-page":"846","volume":"48","author":"MMY Lee","year":"2025","unstructured":"Lee\u00a0MMY, Sattar\u00a0N, Pop-Busui\u00a0R, et\u00a0al. Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials. Diabetes Care. 2025;48(5):846\u201359.","journal-title":"Diabetes Care"},{"issue":"1","key":"2073_CR33","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12933-021-01386-4","volume":"20","author":"M Konig","year":"2021","unstructured":"Konig\u00a0M, Riddle\u00a0MC, Colhoun\u00a0HM, et\u00a0al. Exploring potential mediators of the cardiovascular benefit of dulaglutide in type\u00a02 diabetes patients in REWIND. Cardiovasc Diabetol. 2021;20(1):194\u2013194.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2073_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-03007-w","volume":"24","author":"ZY Peng","year":"2025","unstructured":"Peng\u00a0ZY, Lee\u00a0YH, Ou\u00a0HT, Kuo\u00a0S. Temporal and subgroup disparities in mediation effects on cardiovascular outcomes with liraglutide and semaglutide: a post-hoc analysis of LEADER and SUSTAIN\u20116 trials. Cardiovasc Diabetol. 2025;24(1)465.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2073_CR35","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12933-022-01585-7","volume":"21","author":"O Mosenzon","year":"2022","unstructured":"Mosenzon\u00a0O, Capehorn\u00a0MS, De Remigis\u00a0A, et\u00a0al. Impact of semaglutide on high-sensitivity C\u2011reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials. Cardiovasc Diabetol. 2022;21(1):172\u2013172.","journal-title":"Cardiovasc Diabetol"},{"issue":"10278","key":"2073_CR36","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies\u00a0M, F\u00e6rch\u00a0L, Jeppesen\u00a0OK, et\u00a0al. Semaglutide 2\u00b74\u202fmg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971\u201384.","journal-title":"Lancet"},{"issue":"10516","key":"2073_CR37","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/S0140-6736(25)01375-3","volume":"406","author":"J Deanfield","year":"2025","unstructured":"Deanfield\u00a0J, Lincoff\u00a0AM, Kahn\u00a0SE, et\u00a0al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a\u00a0prespecified analysis of the SELECT trial. Lancet. 2025;406(10516):2257\u201368.","journal-title":"Lancet"},{"issue":"12","key":"2073_CR38","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod\u00a0MN, Abildstrom\u00a0SZ, Borlaug\u00a0BA, et\u00a0al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069\u201384.","journal-title":"N Engl J Med"},{"issue":"15","key":"2073_CR39","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod\u00a0MN, Petrie\u00a0MC, Borlaug\u00a0BA, et\u00a0al. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. N Engl J Med. 2024;390(15):1394\u2013407.","journal-title":"N Engl J Med"},{"issue":"5","key":"2073_CR40","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer\u00a0M, Zile\u00a0MR, Kramer\u00a0CM, et\u00a0al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427\u201337.","journal-title":"N Engl J Med"},{"issue":"7","key":"2073_CR41","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.cardfail.2025.01.022","volume":"31","author":"SA Waqas","year":"2025","unstructured":"Waqas\u00a0SA, Sohail\u00a0MU, Saad\u00a0M, et\u00a0al. Efficacy of GLP\u20111 Receptor Agonists in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. J\u00a0Card Fail. 2025;31(7):1076\u201380.","journal-title":"J Card Fail"},{"issue":"9","key":"2073_CR42","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/ejhf.1902","volume":"22","author":"M Packer","year":"2020","unstructured":"Packer\u00a0M, Lam\u00a0CSP, Lund\u00a0LH, et\u00a0al. Characterization of the inflammatory-metabolic phenotype of heart failure with a\u00a0preserved ejection fraction. Eur J Heart Fail. 2020;22(9):1551\u201367.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"2073_CR43","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jama.2016.10260","volume":"316","author":"KB Margulies","year":"2016","unstructured":"Margulies\u00a0KB, Hernandez\u00a0AF, Redfield\u00a0MM, et\u00a0al. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA. 2016;316(5):500\u20138.","journal-title":"JAMA"},{"issue":"2","key":"2073_CR44","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic\u00a0V, Tuttle\u00a0KR, Rossing\u00a0P, et\u00a0al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"2073_CR45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","volume":"13","author":"SV Badve","year":"2025","unstructured":"Badve\u00a0SV, Bilal\u00a0A, Lee\u00a0MMY, et\u00a0al. Effects of GLP\u20111 receptor agonists on kidney and cardiovascular disease outcomes: a\u00a0meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025;13(1):15\u201328.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10489","key":"2073_CR46","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","volume":"405","author":"MP Bonaca","year":"2025","unstructured":"Bonaca\u00a0MP, Catarig\u00a0AM, Houlind\u00a0K, et\u00a0al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet. 2025;405(10489):1580\u201393.","journal-title":"Lancet"},{"issue":"7","key":"2073_CR47","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1007\/s11606-023-08589-3","volume":"39","author":"Y Xu","year":"2024","unstructured":"Xu\u00a0Y, Boyle\u00a0TA, Lyu\u00a0B, et\u00a0al. Glucagon-like peptide\u20111 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study. J\u00a0Gen Intern Med. 2024;39(7):1112\u201321.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"2073_CR48","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.125.014101","volume":"19","author":"S Venier","year":"2026","unstructured":"Venier\u00a0S, Defaye\u00a0P, Lochon\u00a0L, et\u00a0al. Impact of GLP\u20111 Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis. Circ Arrhythm Electrophysiol. 2026;19(1)e014101.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"1","key":"2073_CR49","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jacc.2025.04.042","volume":"86","author":"P Osmancik","year":"2025","unstructured":"Osmancik\u00a0P, Roubicek\u00a0T, Havranek\u00a0S, et\u00a0al. Catheter Ablation vs Lifestyle Modification With Antiarrhythmic Drugs to Treat Atrial Fibrillation: PRAGUE-25 Trial. J\u00a0Am Coll Cardiol. 2025;86(1):18\u201328.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"2073_CR50","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.jacc.2025.08.027","volume":"86","author":"M Galli","year":"2025","unstructured":"Galli\u00a0M, Benenati\u00a0S, Laudani\u00a0C, et\u00a0al. Cardiovascular Effects and Tolerability of GLP\u20111 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients. J\u00a0Am Coll Cardiol. 2025;86(20):1805\u201319.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2073_CR51","doi-asserted-by":"publisher","first-page":"199","DOI":"10.7326\/ANNALS-24-01590","volume":"178","author":"A Moiz","year":"2025","unstructured":"Moiz\u00a0A, Filion\u00a0KB, Toutounchi\u00a0H, et\u00a0al. Efficacy and Safety of Glucagon-Like Peptide\u20111 Receptor Agonists for Weight Loss Among Adults Without Diabetes: A Systematic Review of Randomized Controlled Trials. Ann Intern Med. 2025;178(2):199\u2013217.","journal-title":"Ann Intern Med"},{"issue":"3","key":"2073_CR52","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1210\/en.2011-1864","volume":"153","author":"LW Madsen","year":"2012","unstructured":"Madsen\u00a0LW, Knauf\u00a0JA, Gotfredsen\u00a0C, et\u00a0al. GLP\u20111 Receptor Agonists and the Thyroid: C\u2011Cell Effects in Mice Are Mediated via the GLP\u20111 Receptor and not Associated with RET Activation. Endocrinology. 2012;153(3):1538\u201347.","journal-title":"Endocrinology"},{"issue":"3","key":"2073_CR53","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","volume":"31","author":"Y Xie","year":"2025","unstructured":"Xie\u00a0Y, Choi\u00a0T, Al-Aly\u00a0Z. Mapping the effectiveness and risks of GLP\u20111 receptor agonists. Nat Med. 2025;31(3):951\u201362.","journal-title":"Nat Med"},{"key":"2073_CR54","doi-asserted-by":"crossref","unstructured":"Ayoub M, Chela H, Amin N, et\u00a0al. Pancreatitis Risk Associated with GLP\u20111 Receptor Agonists, Considered as a\u00a0Single Class, in a\u00a0Comorbidity-Free Subgroup of Type\u00a02 Diabetes Patients in the United States: A\u00a0Propensity Score-Matched Analysis. J\u00a0Clin Med. 2025;14(3).","DOI":"10.3390\/jcm14030944"},{"issue":"3","key":"2073_CR55","first-page":"124","volume":"71","author":"W Masson","year":"2024","unstructured":"Masson\u00a0W, Lobo\u00a0M, Barbagelata\u00a0L, et\u00a0al. Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis. Endocrinol Diabetes Nutr (Engl Ed). 2024;71(3):124\u201332.","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"issue":"36","key":"2073_CR56","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints\u00a0C, Andreotti\u00a0F, Koskinas\u00a0KC, et\u00a0al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415\u2013537.","journal-title":"Eur Heart J"},{"issue":"10","key":"2073_CR57","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1038\/s41591-025-03765-w","volume":"31","author":"B McGowan","year":"2025","unstructured":"McGowan\u00a0B, Ciudin\u00a0A, Baker\u00a0JL, et\u00a0al. Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO). Nat Med. 2025;31(10):3229\u201332.","journal-title":"Nat Med"},{"key":"2073_CR58","unstructured":"Zorginstituut Nederland. Available from: www.zorginstituutnederland.nl."},{"key":"2073_CR59","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-085304","volume":"392","author":"S West","year":"2026","unstructured":"West\u00a0S, Scragg\u00a0J, Aveyard\u00a0P, et\u00a0al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026;392:e085304.","journal-title":"BMJ"},{"issue":"1","key":"2073_CR60","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne\u00a0LJ, Sattar\u00a0N, Horn\u00a0DB, et\u00a0al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT\u20114 Randomized Clinical Trial. JAMA. 2024;331(1):38\u201348.","journal-title":"JAMA"},{"issue":"18","key":"2073_CR61","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","volume":"384","author":"JR Lundgren","year":"2021","unstructured":"Lundgren\u00a0JR, Janus\u00a0C, Jensen\u00a0SBK, et\u00a0al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. N Engl J Med. 2021;384(18):1719\u201330.","journal-title":"N Engl J Med"},{"issue":"2","key":"2073_CR62","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1210\/endrev\/bnaf036","volume":"47","author":"JW Son","year":"2026","unstructured":"Son\u00a0JW, le Roux\u00a0CW, Bl\u00fcher\u00a0M, et\u00a0al. Novel GLP-1-based Medications for Type 2 Diabetes and Obesity. Endocr Rev. 2026;47(2):159\u201377.","journal-title":"Endocr Rev"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-026-02073-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12471-026-02073-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-026-02073-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:02:59Z","timestamp":1790352179000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12471-026-02073-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":62,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2073"],"URL":"https:\/\/doi.org\/10.1007\/s12471-026-02073-3","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.J.F.\u00a0van Maren, E.P.M.\u00a0van Doorn, C.J.J.\u00a0Tack, E.F.C.\u00a0van Rossum and S.\u00a0El Messaoudi declare that they have no competing interests. M.M.\u00a0Smits has received research grants from Novo Nordisk and speaker fees from Eli Lilly and Boehringer Ingelheim (all paid to the institution).","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}